Trial Profile
The prospective and open phase II clinical trial of whole brain radiotherapy combined with anti-angiogenesis therapy for wild-type EGFR non-squamous NSCLC with multiple brain metastases
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Mar 2018 New trial record